Children | Adolescents | Adults | Total | |
---|---|---|---|---|
Patients, N (%) | 108 (36.0) | 30 (10.0) | 162 (54.0) | 300 (100) |
Exposure to trial medication | ||||
Mean days of exposure to trial drug (SD) | 7.1 (1.3) | 6.8 (1.4) | 7.2 (1.8) | 7.1 (1.6) |
Median days of exposure to trial drug | 7 | 6 | 7 | 7 |
Minimum | 4 | 5 | 3 | 3 |
Maximum | 10 | 9 | 12 | 12 |
Patients’ tolerability assessment, N (%) | ||||
Very good | 100 (92.6) | 25 (83.3) | 105 (64.8) | 236 (78.7) |
Good | 7 (6.5) | 5 (16.7) | 50 (30.9) | 64 (21.3) |
Fair | 1 (0.9) | 0 (0.0) | 6 (3.7) | 7 (2.3) |
Poor | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Missing | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Investigators’ tolerability assessment, N (%) | ||||
Very good | 101 (93.6) | 26 (86.7) | 109 (67.3) | 236 (78.7) |
Good | 7 (6.5) | 4 (13.3) | 53 (32.7) | 64 (21.3) |
Fair | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Poor | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |